MyLife Technologies secures new growth capitalTuesday, November 15, 2016
The company focuses on applications in the field of prophylactic vaccines, therapeutic vaccines and specific small molecules. The npMNAs are made of biocompatible ceramic material and are combined with a dermal patch, allowing easy self-application by the patient. The nanopores of the MNA devices are used for storage of pharmaceutical compounds. This minimally invasive application method is pain-free and is an effective way to overcome the stratum corneum, the skin’s main barrier.
MyLife Technologies is a spin-off from University of Twente, MESA+, Institute for Nanotechnology, The Netherlands. In June 2015, the company opened its own lab in the facilities of BioPartner Center at Leiden Bio Science Park. Technology patents have been obtained in Europe, USA, Japan and China.
CEO Pieter Jan Vos is very pleased: “This new capital is an important milestone for MyLife Technologies. It allows us to expand our lab facilities and our team. We will intensify and expand our development pipeline”.
ISA Pharmaceuticals strengthens its supervisory board with the addition of Dr. Markwin Velders
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
European Medicines Agency validates marketing application for Filgotinib for the treatment of rheumatoid arthritis